BLUE - bluebird bio, Inc.
119.68 0.00 (0.00%)
After hours: 5:54PM EDT
| Previous Close | 118.32 |
| Open | 119.20 |
| Bid | 119.78 x 1300 |
| Ask | 119.84 x 900 |
| Day's Range | 117.35 - 120.77 |
| 52 Week Range | 87.49 - 189.31 |
| Volume | 697,214 |
| Avg. Volume | 476,651 |
| Market Cap | 6.597B |
| Beta (3Y Monthly) | 3.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.35 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 175.44 |
- Investor's Business Daily•2 days ago
Why This Biotech's Approved Gene Therapy Won't Launch Until 2020
Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene therapy in Europe and the U.S. until 2020 and 2021, respectively.
- Markit•2 days ago
See what the IHS Markit Score report has to say about bluebird bio Inc.
bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BLUE are favorable, with net inflows of $3.11 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey•3 days ago
Is bluebird bio Inc (BLUE) A Good Stock To Buy?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
- Motley Fool•5 days ago
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
- Barrons.com•6 days ago
Bluebird Bio’s Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.
(BLUE) will sell a gene-therapy treatment for the disease beta-thalassemia for $1.8 million per patient, but the money won’t start coming in as soon as expected. The drug, Zynteglo—the second-most-expensive in the world, according to The Wall Street Journal—received conditional marketing authorization from the European Union early this month. The treatment has yet to be approved by the Food and Drug Administration.
- American City Business Journals•6 days ago
Bluebird prices gene therapy in Europe at $1.8M over 5 years
Th Cambridge biotech set a price tag of $1.8 million spread over five years (315,000 euros per year, or the equivalent of $356,000 annually) for its first commercial drug on Friday, for which it received approval to sell in Europe last week.
- Business Wire•6 days ago
bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
Up to 3.8 years of transfusion independence in Phase 1/2 Northstar study in patients with TDT who do not have a β0/β0 genotype
- Business Wire•6 days ago
bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin was reduced to ≤50 percent of total Hb
- Financial Times•6 days ago
Bluebird Bio prices gene therapy at nearly $1.8m
Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.
- American City Business Journals•6 days ago
Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.
- Simply Wall St.•8 days ago
bluebird bio (NASDAQ:BLUE) Shareholders Have Enjoyed An Impressive 223% Share Price Gain
While bluebird bio, Inc. (NASDAQ:BLUE) shareholders are probably generally happy, the stock hasn't had particularly...
- Business Wire•14 days ago
bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval
To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event. bluebird bio is pioneering gene therapy with purpose.
- American City Business Journals•14 days ago
Life sciences VC firm Third Rock raises $770M in its largest round ever
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
- Zacks•16 days ago
bluebird's Zynteglo Gets EU Conditional Marketing Approval
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
- Motley Fool•16 days ago
It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
- Business Wire•17 days ago
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia
- Zacks•19 days ago
Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report?
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•20 days ago
bluebird bio Announces Investor Events in June
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully.
- Kiplinger•21 days ago
Save the Date: 11 Biotech Stocks to Put on Your Radar
This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of
- Insider Monkey•26 days ago
Marshall Wace’s Latest Moves
Back in 1997, Paul Marshall and Ian Wace launched their own hedge fund called Marshall Wace. The fund is headquartered in London, England while providing additional offices in New York, and Hong Kong. The fund’s investment philosophy combines quantitative strategies with basic investment principles for the purpose of delivering strong returns to its clients. Its […]
